Anthracycline-Induced Cardiotoxicity

Anthracycline antibiotics are among the most effective and widely used antineoplastic drugs. Their usefulness is limited by a cumulative dose-related cardiotoxicity, whose precise mechanisms are not clear as yet. The principal role is possibly exerted by free oxygen radicals generated by “redox-cycl...

Full description

Bibliographic Details
Published in:	Acta Medica
Main Authors:	Radomír Hrdina, Vladimír Geršl, Ivona Klimtová, Tomáš Šimůnek, Jarmila Macháčková, Michaela Adamcová
Format:	Article
Language:	English
Published:	Karolinum Press 2000-01-01
Subjects:	Anthracyclines Cardioprotection Cardiotoxicity Daunorubicin Dexrazoxane Doxorubicin
Online Access:	https://actamedica.lfhk.cuni.cz/43/3/0075/

Similar Items

Effect of Sodium 2,3-Dimercaptopropane-1-Sulphonate (DMPS) on Chronic Daunorubicin Toxicity in Rabbits: Comparison with Dexrazoxane
by: Radomír Hrdina, et al.
Published: (2002-01-01)

Anthracycline-induced cardiac toxicity: A clinical review
by: Adil Abdelhameed Abbas, et al.
Published: (2019-01-01)

Efficacy of Dexrazoxane in Preventing Anthracycline Cardiotoxicity in Breast Cancer
by: Ariane V.S. Macedo, MD, MSc, et al.
Published: (2019-09-01)

Electrocardiographic characteristics of Nigerian children on anthracycline-based chemotherapy: A preliminary report
by: I D Peter, et al.
Published: (2017-01-01)

Cardioprotective potential of botanical agents against anthracycline-induced cardiotoxicity
by: Parisa Firoozbakhsh, et al.
Published: (2024-05-01)

Anthracycline-induced cardiotoxicity – primary preventive options. An overview
by: S. Slavcheva
Published: (2024-05-01)

Evaluation of the cost-effectiveness of dexrazoxane for the prevention of anthracycline-related cardiotoxicity in children with sarcoma and haematologic malignancies: a European perspective
by: Sarah Dewilde, et al.
Published: (2020-02-01)

Challenges in the implementation of cardio-oncology trials: lessons learnt from investigating statins in the prevention of anthracycline cardiotoxicity
by: John Lee, et al.
Published: (2024-12-01)

Safety Evaluation of the Combination with Dexrazoxane and Anthracyclines: A Disproportionality Analysis Based on the Food and Drug Administration Adverse Event Reporting System Database
by: Danyi Liu, et al.
Published: (2024-12-01)

Temporal Dynamics of Extracellular Matrix Remodeling in Anthracycline-Induced Cardiotoxicity
by: Fibi Meshrkey, et al.
Published: (2025-09-01)

Clinical and preclinical evidence of sex-related differences in anthracycline-induced cardiotoxicity
by: Becky Meiners, et al.
Published: (2018-08-01)

A Pilot Study of Matrix Metalloproteinases on the Model of Daunorubicin-induced Cardiomyopathy in Rabbits
by: Anna Potáčová, et al.
Published: (2007-01-01)

Cardiotoxicity of Non-Anthracycline Cancer Chemotherapy Agents
by: Alexandros Briasoulis, et al.
Published: (2022-02-01)

Creation of anthracycline prodrug
by: A. N. Tevyashova
Published: (2014-12-01)

Prevention of Anthracycline-Induced Cardiotoxicity: The Good and Bad of Current and Alternative Therapies
by: Nonhlakanipho F. Sangweni, et al.
Published: (2022-06-01)

Prevention and management of anthracycline induced cardiotoxicity: A review
by: Ian Osoro, et al.
Published: (2022-12-01)

Therapeutic Potential of Ginsenosides in Anthracycline-Induced Cardiotoxicity
by: Rongrong Bai, et al.
Published: (2025-06-01)

Can Dexrazoxane and Carvedilol prevent Doxorubicin-induced nephrotoxicity?
by: Szponar Jaroslaw, et al.
Published: (2024-12-01)

High Density Lipoprotein and Its Precursor Protein Apolipoprotein A1 as Potential Therapeutics to Prevent Anthracycline Associated Cardiotoxicity
by: George E. G. Kluck, et al.
Published: (2020-04-01)

Comparative study on the protective effect of dexrazoxane and blueberry extract against doxorubicin-induced cardiotoxicity in rats
by: Nourhan Ahmed Shaker, et al.
Published: (2025-09-01)

Protection against Doxorubicin-Induced Cardiotoxicity by Ergothioneine
by: Irwin K. Cheah, et al.
Published: (2023-01-01)

Evaluating cardioprotective strategies for anthracycline-induced cardiotoxicity in breast cancer: insights from a systematic review and network meta-analysis
by: Runyu Liu, et al.
Published: (2025-07-01)

N-Alkylation of Anthracycline Antibiotics by Natural Sesquiterpene Lactones as a Way to Obtain Antitumor Agents with Reduced Side Effects
by: Margarita Neganova, et al.
Published: (2021-05-01)

The Role of Flavonoids as a Cardioprotective Strategy against Doxorubicin-Induced Cardiotoxicity: A Review
by: Rony Abdi Syahputra, et al.
Published: (2022-02-01)

Cardiotoxicity in Breast Cancer Therapy: Risks, Mechanisms, and Prevention Strategies
by: Annisa Eka Fitrianti, et al.
Published: (2025-08-01)

Cardiotoxicity of doxorubicin – causes, prevention, prospects
by: Paweł Wesołowski, et al.
Published: (2022-11-01)

Potential Roles of Melatonin in Doxorubicin-Induced Cardiotoxicity: From Cellular Mechanisms to Clinical Application
by: Tanawat Attachaipanich, et al.
Published: (2023-02-01)

Anthracycline-induced cardiotoxicity: mechanisms, monitoring, and prevention
by: Yun Qiu, et al.
Published: (2023-12-01)

Exercise to Reduce Anthracycline-Mediated Cardiovascular Complications in Breast Cancer Survivors
by: Sonu S. Varghese, et al.
Published: (2021-10-01)

Pyridoxamine Limits Cardiac Dysfunction in a Rat Model of Doxorubicin-Induced Cardiotoxicity
by: Sibren Haesen, et al.
Published: (2024-01-01)

Erythrocytes as carriers of anthracycline antibiotics
by: A G Tikhonova, et al.
Published: (2008-07-01)

Assessment of anthracycline-induced long-term cardiotoxicity in patients with hematological malignancies
by: Aws Sabah Al-Rubaye, et al.
Published: (2019-01-01)

Rationale and design of the HOVON 170 DLBCL-ANTICIPATE trial: preventing anthracycline-induced cardiac dysfunction with dexrazoxane
by: Marijke Linschoten, et al.
Published: (2025-01-01)

Potential effects of pomegranate on lipid peroxidation and pro-inflammatory changes in daunorubicin-induced cardiotoxicity in rats
by: Hayder M Al-Kuraishy, et al.
Published: (2016-01-01)

The Impact of Polymorphisms in ATP-Binding Cassette Transporter Genes on Anthracycline-Induced Early Cardiotoxicity in Patients with Breast Cancer
by: Gintare Muckiene, et al.
Published: (2023-05-01)

Mechanistic Insights into Flavonoid Subclasses as Cardioprotective Agents Against Doxorubicin-Induced Cardiotoxicity: A Comprehensive Review
by: Shang W, et al.
Published: (2025-07-01)

An update of the molecular mechanisms underlying anthracycline induced cardiotoxicity
by: Sicong Xie, et al.
Published: (2024-06-01)

RISK FACTORS AND INCIDENCE OF MYOCARDIAL DAMAGE IN PATIENTS WITH HEMOBLASTOSIS RECEIVING ANTHRACYCLIN ANTIBIOTICS
by: N. T. Vatutin, et al.
Published: (2017-10-01)

Racial and Ethnic Disparities in Cardiotoxicity in Patients With Cancer Treated With Anthracyclines
by: Lili Zhang, et al.
Published: (2025-04-01)

Correction: An update of the molecular mechanisms underlying anthracycline induced cardiotoxicity
by: Sicong Xie, et al.
Published: (2025-09-01)